Outside the lab, Frank McCormick, PhD, FAACR, is a racecar driver, nurturing a passion he developed decades ago. (“We all need hobbies, right?” he says with a grin.) Inside the lab, he uses a...
Physicians consider which patients are ideal for immunotherapy drug combinations.
Protein signatures in the blood could help guide physicians in choosing among different immunotherapy drugs.
Study results show stereotactic body radiation therapy could be added to standard care.
Theranostics offers the promise of combining diagnosis and treatment.
A small study finds no cancer recurrences after two years in patients who skipped breast surgery following a complete response to chemotherapy—but experts say the research is in its very early stages.
A recent study investigated why some young cancer survivors did not want the HPV vaccine and how they can be better served.
Drug shortage affects patients with advanced prostate cancer, and military pilots and ground crews have increased cancer rates.
How the latest clinical therapies are helping patients and laboratory research informing future treatments.
The FDA has approved the monoclonal antibody retifanlimab-dlwr for some patients with Merkel cell carcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to retifanlimab-dlwr (Zynyz) for the treatment of adult...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More